Lilly advances TRB-051 in lupus as TRexBio unveils the mechanism behind TRB-071
Explore how TRexBio’s TRB-071 CD30 agonist and Lilly-partnered TRB-051 could reshape tissue Treg drug development. Read the analysis.
Pharma & Biotech
Pharma & Biotech
Entyvio pediatric filing puts Takeda at the centre of the next IBD treatment debate
Find out how Takeda’s pediatric Entyvio review could change biologic treatment choices in ulcerative colitis and Crohn’s disease.
Pharma & Biotech
Accro Bioscience’s $50m round signals growing interest in targeted IBD immunology
IBD needs safer oral options. Accro’s $50 million raise puts RIPK2 inhibition closer to a decisive clinical test.
Pharma & Biotech
Mabwell’s 9MW5211 gets FDA clearance, but can a first-in-class autoimmune antibody break through?
Mabwell has FDA clearance for 9MW5211. The bigger test is whether a first-in-class autoimmune antibody can prove durable remission.
Pharma & Biotech
Early-stage biosimilar deal between Samsung Bioepis and Sandoz covers vedolizumab and four undisclosed molecules
Samsung Bioepis and Sandoz expand their biosimilar partnership to cover vedolizumab SB36 and four early-stage candidates. What this means for the IBD biologics market.
Pharma & Biotech
AbbVie’s AFFIRM trial: what clinicians should watch next for risankizumab in Crohn’s disease
AbbVie reports positive Phase 3 AFFIRM trial results for risankizumab subcutaneous induction in Crohn’s disease. Discover what the findings mean for treatment.
Pharma & Biotech
Johnson & Johnson’s three-year TREMFYA data sharpen the durability debate in ulcerative colitis care
Johnson & Johnson’s three-year TREMFYA data highlight why sustained remission is redefining ulcerative colitis treatment decisions. Read the analysis.
Pharma & Biotech
NIM-1324 enters Phase 2 as NImmune Biopharma tests immunometabolism as the next frontier in inflammatory bowel disease
Discover how NImmune Biopharma’s NIM-1324 Phase 2 program could reshape inflammatory bowel disease treatment beyond biologics and JAK inhibitors.
Pharma & Biotech
Nimbus Therapeutics tests a dual inflammation and repair thesis with SIK2 inhibitors
Nimbus Therapeutics unveils SIK2 inhibitor data at ECCO 2026. Explore what this means for oral IBD therapies and mucosal healing strategies.
Pharma & Biotech
Can subcutaneous infliximab change how clinicians manage drug holidays in Crohn’s disease and ulcerative colitis
New ECCO 2026 data explore whether subcutaneous infliximab can reliably recapture disease control after treatment interruption. Read the analysis.